These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32590421)

  • 1. Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero.
    Clark R; Lindsey D; Whiteway S; Mikita C; Lieuw K
    J Pediatr Hematol Oncol; 2021 May; 43(4):e601-e604. PubMed ID: 32590421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
    Sacco KA; Abraham RS
    Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal malakoplakia in a patient with hypogammaglobulinemia.
    Thorlacius H; Jerkeman A; Marginean FE; Toth E
    Gastrointest Endosc; 2018 Sep; 88(3):563-565. PubMed ID: 29627491
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
    JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen.
    Mandal PK; Dolai TK; Bagchi B; Ghosh MK; Bose S; Bhattacharyya M
    Indian J Pediatr; 2014 Oct; 81(10):1092-4. PubMed ID: 24562617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.
    Luterbacher F; Bernard F; Baleydier F; Ranza E; Jandus P; Blanchard-Rohner G
    Front Immunol; 2021; 12():773853. PubMed ID: 35003091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?
    Barmettler S; Price C
    J Allergy Clin Immunol; 2015 Nov; 136(5):1407-9. PubMed ID: 26277594
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
    Filanovsky K; Miller EB; Sigler E; Berrebi A; Shvidel L
    Recent Pat Anticancer Drug Discov; 2016; 11(2):228-35. PubMed ID: 26825174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
    Gonzalez Caldito N; Graham EL; Grebenciucova E
    Mult Scler; 2024 Feb; 30(2):272-274. PubMed ID: 38116592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.
    Athni TS; Barmettler S
    Ann Allergy Asthma Immunol; 2023 Jun; 130(6):699-712. PubMed ID: 36706910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
    Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
    Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases.
    Malpica Castillo LE; Palmer S; Zhu A; Deal AM; Chen SL; Moll S
    Am J Hematol; 2020 May; 95(5):E117-E120. PubMed ID: 32017201
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
    Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
    Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
    Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-associated colitis.
    Barreiro Alonso E; Álvarez Álvarez A; Tojo González R; de la Coba Ortiz C
    Gastroenterol Hepatol; 2019 Apr; 42(4):251-252. PubMed ID: 29884483
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
    Kridin K; Ahmed AR
    Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
    Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
    Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL.
    Kosmidis S; Baka M; Bouhoutsou D; Doganis D; Kallergi C; Douladiris N; Pourtsidis A; Varvoutsi M; Saxoni-Papageorgiou F; Vasilatou-Kosmidis H
    Pediatr Blood Cancer; 2008 Mar; 50(3):528-32. PubMed ID: 17853465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.